Nubeqa for non-metastatic castration-resistant prostate cancer, approved by FDA
The Food and Drug Administration ( FDA ) has approved Nubeqa ( Darolutamide ) for non-metastatic castration-resistant prostate cancer.
Approval was based on ARAMIS, a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer.
Patients were randomized ( 2:1 ) to receive either 600 mg Darolutamide orally twice daily ( n=955 ) or matching placebo ( n=554 ).
All patients received a gonadotropin-releasing hormone ( GnRH ) analog concurrently or had a previous bilateral orchiectomy.
Twelve patients with previous seizure histories were treated on the Darolutamide arm.
The primary endpoint was metastasis free survival ( MFS ), defined as the time from randomization to first evidence of distant metastasis or death from any cause within 33 weeks after the last evaluable scan, whichever occurred first.
The median MFS was 40.4 months ( 95% CI: 34.3, not reached ) for patients treated with Darolutamide compared with 18.4 months ( 95% CI: 15.5, 22.3 ) for those receiving placebo ( hazard ratio, HR=0.41; 95% CI: 0.34, 0.50; p less than 0.0001 ).
Overall survival ( OS ) data were not mature.
The most common adverse reactions ( greater than or equal to 2% ) in patients who received Darolutamide were fatigue, pain in extremity, and rash.
Ischemic heart disease ( 4.3% ) and heart failure ( 2.1% ) were more common on the Darolutamide arm.
The seizure incidence was similar on the two arms ( 0.2% ).
The recommended Darolutamide dose is 600 mg ( two 300 mg tablets ) administered orally twice daily with food.
Patients should also receive a gonadotropin-releasing hormone ( GnRH ) analog concurrently or should have had bilateral orchiectomy. ( Xagena )
Source: FDA, 2019
FDA has approved Emgality, the first treatment for episodic cluster headache that reduces the frequency of attacks
The FDA ( U.S. Food and Drug Administration ) has approved Emgality ( Galcanezumab-gnlm; Galcanezumab ) solution for injection for...
Relapsed and refractory multiple myeloma: European Commission has approved Empliciti plus Pomalidomide and low-dose Dexamethasone
The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd )...
Direct-acting antivirals reduce risk of premature mortality and liver cancer for patients with chronic hepatitis C
The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated...
Satralizumab, an anti-IL-6 receptor monoclonal antibody, reduces relapse risk for neuromyelitis optica spectrum disorder
Full pivotal phase III SAkuraStar study results for Satralizumab as a monotherapy for neuromyelitis optica spectrum disorder ( NMOSD ),...
FDA has approved treatment for patients with endometrial carcinoma: Lenvima in combination with Keytruda
The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...
Adults and children with all genotypes of hepatitis C and compensated cirrhosis: Mavyret shortens duration of treatment to eight weeks, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...
FDA has approved Ofev, first treatment for patients with interstitial lung disease associated with systemic sclerosis or scleroderma
The FDA ( U.S. Food and Drug Administration ) has approved Ofev ( Nintedanib ) capsules to slow the rate...
Standard methods to detect NTRK fusions in daily practice and clinical research: ESMO recommendations
NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most...